Cost-Effectiveness of Thrombolytic Therapy, Compared with Anticoagulants Therapy in the Treatment of Acute Myocardial Infarction in Albania.
OBJECTIVE
The study aim is to evaluate the cost-effectiveness of thrombolytic treatment in acute MI comparing with anticoagulants therapy and between each other thrombolytic (SK, r-Pa).


METHODS
We used a prospective registry of all patients admitted for acute myocardial infarction in intensive care units in Tirana. The average drugs cost was calculated for the hospitalization period in Albanian money (ALL). Survival and life quality were estimated by phone contact 1 year after acute MI.


RESULTS
Anticoagulant group cost is 23865.3 ALL (170.5€), SK group cost is 54148.63 ALL (386.7€), r-Pa group has a cost of 92184.90 ALL (658.5€). In the group treated with SK the hospital survival is 100%, while in the control group 88.8%. Reteplase group has a lower period of stay in hospital than SK group 13.04 days vs. 17.97 days, mean age in group treated with r-Pa is 64.29 ± 10.03 approximate with anticoagulant group mean age 64.17 ± 11.08; differ significantly with SK group mean age 56.75 ± 10.04. Survival after 1 year was 96.4% for r-Pa and 96.9% SK.


CONCLUSIONS
SK and r-Pa are successful thrombolytics with high effectiveness. It is gained a higher survival with the thrombolytic treatments. Reteplase is well tolerated in older patients than SK, is easier to apply than Streptokinase, but has higher cost.
Pharmaceutical Service "Mother Teresa" Hospital, Tirana, Albania.
Mirvete
M
Rama
Medicine University, Faculty of Pharmacy, Tirana, Albania.
Mirela
M
Miraci
University Hospital Center "Mother Theresa", Tirana, Albania.
Idriz
I
Balla
Medicine University, Public Health Faculty, Tirana, Albania.
Ela
E
Petrela
Medicine University, Faculty of Pharmacy, Tirana, Albania.
Ledjan
L
Malaj
Bayer Representation Office, Tirana, Albania.
Anjeza
A
Koleci
Acute Myocardial Infarction; Cost-effectiveness; Reteplase(r-Pa); Streptokinase (SK); Thrombolytics; anticoagulants